Mobit P N, Packianathan S, He R, Yang C C
1 Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA.
2 Cameroon Oncology Center, PO Box 1870, Douala, Cameroon.
Br J Radiol. 2015 Aug;88(1052):20150010. doi: 10.1259/bjr.20150010. Epub 2015 May 21.
To evaluate the dosimetric differences and similarities between treatment plans generated with Axxent-Xoft electronic brachytherapy source (Xoft-EBS), (192)Ir and (60)Co for tandem and ovoids (T&O) applicators.
In this retrospective study, we replanned 10 patients previously treated with (192)Ir high-dose-rate brachytherapy. Prescription was 7 Gy × 4 fractions to Point A. For each original plan, we created two additional plans with Xoft-EBS and (60)Co. The dose to each organ at risk (OAR) was evaluated in terms of V(35%) and V(50%), the percentage volume receiving 35% and 50% of the prescription dose, respectively, and D(2cc), highest dose to a 2 cm(3) volume of an OAR.
There was no difference between plans generated by (192)Ir and (60)Co, but the plans generated using Xoft-EBS showed a reduction of up to 50% in V(35%), V(50%) and D(2cc). The volumes of the 200% and 150% isodose lines, however, were 74% and 34% greater than the comparable volumes generated with the (192)Ir source. Point B dose was on average only 16% of the Point A dose for plans generated with Xoft-EBS compared with 30% for plans generated with (192)Ir or (60)Co.
The Xoft-EBS can potentially replace either (192)Ir or (60)Co in T&O treatments. Xoft-EBS offers either better sparing of the OARs compared with (192)Ir or (60)Co or at least similar sparing. Xoft-EBS-generated plans had higher doses within the target volume than (192)Ir- or (60)Co-generated ones.
This work presents newer knowledge in dosimetric comparison between Xoft-EBS, (192)Ir or (60)Co sources for T&O implants.
评估使用Axxent-Xoft电子近距离放射治疗源(Xoft-EBS)、铱-192(¹⁹²Ir)和钴-60(⁶⁰Co)为串形和卵圆形施源器(T&O)生成的治疗计划之间的剂量差异和相似性。
在这项回顾性研究中,我们对10例先前接受过铱-192高剂量率近距离放射治疗的患者重新制定计划。处方剂量为A点7 Gy×4次分割。对于每个原始计划,我们使用Xoft-EBS和钴-60创建了另外两个计划。根据V(35%)和V(50%)评估每个危及器官(OAR)的剂量,V(35%)和V(50%)分别是接受35%和50%处方剂量的体积百分比,以及D(2cc),即OAR中2 cm³体积所接受的最高剂量。
铱-192和钴-60生成的计划之间没有差异,但使用Xoft-EBS生成的计划在V(35%)、V(50%)和D(2cc)方面显示最多降低了50%。然而,200%和150%等剂量线的体积比使用铱-192源生成的可比体积分别大74%和34%。与铱-192或钴-60生成的计划相比,Xoft-EBS生成的计划中B点剂量平均仅为A点剂量的16%,而铱-192或钴-60生成的计划中这一比例为30%。
在T&O治疗中,Xoft-EBS有可能替代铱-192或钴-60。与铱-192或钴-60相比,Xoft-EBS对OAR的保护效果更好,或者至少相似。Xoft-EBS生成的计划在靶区内的剂量比铱-192或钴-60生成的计划更高。
这项工作展示了关于Xoft-EBS、铱-192或钴-60源用于T&O植入的剂量学比较的新知识。